Indolin-2-one derivatives as selective Aurora B kinase inhibitors targeting breast cancer

Structural insights of oxindole based kinase inhibitors as anticancer agents: Recent advances

(2021) Prajwal Dhokne et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Aurora Kinase B Inhibition: A Potential Therapeutic Strategy for Cancer

(2021) Naheed Arfin Borah et al.   MOLECULES

The identification and characterisation of autophagy inhibitors from the published kinase inhibitor sets

(2020) Maria Zachari et al.   BIOCHEMICAL JOURNAL

Substituted oxindol-3-ylidenes as AMP-activated protein kinase (AMPK) inhibitors

(2020) Christopher J. Matheson et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Comparative Assessment of Protein Kinase Inhibitors in Public Databases and in PKIDB

(2020) Colin Bournez et al.   MOLECULES

Mining Public Domain Data to Develop Selective DYRK1A Inhibitors

(2020) Scott H. Henderson et al.   ACS Medicinal Chemistry Letters

The importance of indole and azaindole scaffold in the development of antitumor agents

(2020) Yu Han et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression

(2020) Naga Rajiv Lakkaniga et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Targeting fungal virulence factor by small molecules: Structure-based discovery of novel secreted aspartic protease 2 (SAP2) inhibitors

(2020) Chenglan Li et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations

(2019) Dennis Bensinger et al.   JOURNAL OF MEDICINAL CHEMISTRY

Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases

(2019) Viktoriya Ivasiv et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Tuning mTORC1 activity dictates the response of acute myeloid leukemia to LSD1 inhibition

(2019) Amal Kamal Abdel-Aziz et al.   HAEMATOLOGICA

1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC

(2019) Eman M.E. Dokla et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Kinase-targeted cancer therapies: progress, challenges and future directions

(2018) Khushwant S. Bhullar et al.   Molecular Cancer

A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies

(2017) Ankit C. Borisa et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Aurora kinases: novel therapy targets in cancers

(2017) Anqun Tang et al.   Oncotarget

From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib

(2017) Amal Kamal Abdel-Aziz et al.   Frontiers in Pharmacology

Structural analysis of PIM1 kinase complexes with ATP-competitive inhibitors

(2017) Jozefina Bogusz et al.   Scientific Reports

The tyrosine kinase inhibitor, sunitinib malate, induces cognitive impairment in vivo via dysregulating VEGFR signaling, apoptotic and autophagic machineries

(2016) Amal Kamal Abdel-Aziz et al.   EXPERIMENTAL NEUROLOGY

The ChEMBL database in 2017

(2016) Anna Gaulton et al.   NUCLEIC ACIDS RESEARCH

Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor

(2015) Wylie S. Palmer et al.   JOURNAL OF MEDICINAL CHEMISTRY

The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression

(2015) M. S. Phadke et al.   MOLECULAR CANCER THERAPEUTICS

ChEMBL web services: streamlining access to drug discovery data and utilities

(2015) Mark Davies et al.   NUCLEIC ACIDS RESEARCH

Aurora Kinase Inhibitors: Current Status and Outlook

(2015) Vassilios Bavetsias et al.   Frontiers in Oncology

Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?

(2014) Zheng Zhao et al.   ACS Chemical Biology

Modulation of Imatinib Cytotoxicity by Selenite in HCT116 Colorectal Cancer Cells

(2014) Amal Kamal Abdel-Aziz et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Chloroquine synergizes sunitinib cytotoxicity via modulating autophagic, apoptotic and angiogenic machineries

(2014) Amal Kamal Abdel-Aziz et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Aurora B prevents delayed DNA replication and premature mitotic exit by repressing p21Cip1

(2013) Marianna Trakala et al.   CELL CYCLE

Activity-based kinase profiling of approved tyrosine kinase inhibitors

(2012) Daisuke Kitagawa et al.   GENES TO CELLS

Aurora kinase inhibitors: Progress towards the clinic

(2012) Madhu Kollareddy et al.   INVESTIGATIONAL NEW DRUGS

Targeted Kinase Selectivity from Kinase Profiling Data

(2012) Francesca Milletti et al.   ACS Medicinal Chemistry Letters

Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer

(2010) Christopher P Gully et al.   Molecular Cancer

Sunitinib

(2009) Georgios S. Papaetis et al.   BIODRUGS

The discovery of the potent aurora inhibitor MK-0457 (VX-680)

(2009) David Bebbington et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Aurora Kinases as Anticancer Drug Targets

(2008) O. Gautschi et al.   CLINICAL CANCER RESEARCH

Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity†

(2008) Steven Howard et al.   JOURNAL OF MEDICINAL CHEMISTRY